Myeloid cell: CD14
Unlocking T cells for Long-term Immunity & Protection from COVID-19
Historically prophylactic viral vaccines have concentrated on the stimulation of neutralizing antibodies. Many have failed to induce long-term efficacy and protection.
Approaches that activate T cells may overcome this.
Myeloid Vaccine Clinical Programs
Myeloid Cell Vaccine
Prior studies of SARS-CoV-1 and MERS strongly support testing of alternative strategies capable of eliciting SARS-CoV-2-specific
T cell responses.
The current COVID-19 landscape has observed the emergence of vaccines that focus on the generation of neutralizing antibodies. While these efforts are justified, prior studies of SARS-CoV-1 and MERS strongly support testing of alternative strategies capable of eliciting SARS-CoV-2-specific T cell responses. It has been shown that T cell immunity is protective for SARS-CoV and plays an important role in recovery from infection. Suboptimal T cell responses also contribute to the development of severe SARS in animal models, which may explain the high mortality of SARS-CoV-2 in the elderly. In SARS-CoV, cellular immunity may also offer longer protection than antibodies. In patients who have recovered from SARS-CoV infection, anti-viral antibodies are often undetectable, whereas memory T cells have been shown to persist for up to 6 years. In addition, it is possible that the induction of anti-SARS-CoV-2 Abs will increase disease severity.
Multiple studies have suggested that Antibody Dependent Enhancement (ADE) of coronavirus infections occur and, in SARS-CoV/macaque models, anti-S protein IgG has been shown to exacerbate Acute Lung Injury (ALI). For these reasons, it has been suggested that vaccines against emerging coronaviruses should emphasize the generation of a memory CD8+ T cell response. Based on our work with glioblastoma, we have developed a novel SARS-CoV-2 T cell vaccine, referred to as the COVID-19 ATAK™ myeloid cell vaccine.
COVID-19 ATAK™ Programs
Our ATAK™ (Activate Target Attack Kill) vaccine platform enables myeloid cells to stimulate an immune response to viruses and cancers. ATAK™ myeloid cells sustain the ability to cross-present antigen, thereby generating a durable anti-tumor and anti-viral response by cytotoxic T cells.
In preclinical studies of glioblastoma the ATAK™ vaccine demonstrated a reduction in tumor burden.
Programs & Pipeline